ERBB3 and breast carcinoma: The presence of HRG ligands in breast cancer tissues is thought to represent a potential resistance mechanism to anti-HER-2 targeting agents, such as trastuzumab and pertuzumab, as they can activate remnant-non-bound HER-2 receptors through HER-3 binding [14, 53, 54].